Document is current
Any future updates will be listed below
-
Authors
François, Chloé
Carlier, Thomas
Touzeau, Cyrille
Janz, Anna
Dubégny, Constance
Jamet, Bastien
Kraeber-Bodéré, Françoise
Bailly, Clément
Bodet-Milin, Caroline
-
Funding
Funding for this research was provided by:
Direction Générale de l’offre de Soins (INCa-DGOS-INSERM/ITMO (SIRIC ILIAD))
Agence nationale de la recherche (ANR) (France 2030)
Pentixapharm (Fees for endpoints board)
Conseil Régional des Pays de la Loire (Conseil Régional des Pays de la Loire)
- License Information
-
More Information
Article History
Received: 8 January 2026
Accepted: 28 February 2026
First Online: 13 March 2026
Declarations
:
: The study was conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. It was approved by the local ethics committee (Comité de Protection des Personnes Ouest IV, Nantes, France) as part of the PentiMyelo protocol, sponsored by Nantes University Hospital and registered on ClinicalTrials.gov (NCT04561492). Written informed consent was obtained from all participants prior to inclusion.
: Not applicable.
: Pentixapharm AG provided the radiotracer and supported the study. Anna Janz is an employee and owns stock in Pentixapharm AG. The other authors have no conflict of interest to disclose.
